Official Title
Impact of Colchicine in Hospitalized Colombian Patients With COVID-19
Brief Summary

This is a phase IIIa, prospective, open-label, randomized, parallel-group study designed to evaluate the efficacy and safety of oral colchicine plus standard therapy versus standard therapy in the clinical course of SARS-CoV-2 infection, in a population group with moderate COVID-19 compromise and requiring hospitalization.Aproximately 120 subjects meeting all inclusion and not inclusion criteria will be randomized to receive either Colchicine plus standard treatment or only standard treatment for 15 days

Detailed Description

Introduction: COVID-19 and mortality associated with acute respiratory distress syndrome

(ARDS) pose a global public health problem. The increase in spread and associated mortality

poses a scenario where cost-effective therapeutic options are urgently and effectively

proposed to control and reduce the pandemic and even to reduce the number of deaths

Objective: To evaluate the efficacy and safety of oral colchicine plus treatment standard

versus standard treatment in the clinical course of SARS-CoV-2 virus infection, in a

population group with moderate COVID-19 involvement and requiring hospitalization.

Methodology: A prospective, open, randomized, parallel-group study, the sample size of 120

subjects each arm of 60 subjects. Random assignment (1: 1) to either colchicine plus standard

treatment or control arm (standard treatment) orally for 14 days. An initial dose of 1.5 mg

orally on the first day, followed by 0.5 mg every 12 hours on days 2 to 7 and continuing with

0.5 mg a day until completing 14 days ± 1. It will be followed on days 1, 3, 7, 14, and day

28, evaluating physical examination, clinical situation, laboratories, and adverse events.

The primary efficacy data correspond to the deterioration in the clinical status of the

patients through the semiquantitative ordinal scale suggested by the WHO R&D committee.

Expected results: It is expected to find out how, through different pathways, colchicine

could act in modulating or preventing the appearance of ARDS associated with COVID-19, its

possible effects on viral replication and antigenic presentation.

Not yet recruiting
Corona Virus Infection

Drug: Colchicine 0.5 MG
Patientes in this arm will receive study medication colchicine 1,5 orally on the first day (initially two pills of 0,5 mg and 0.5 mg at 2 hours), followed by 0.5 mg every 12 hours on days 2 to 7, and continuing with 0.5 mg per day until completing 14 ± 1 days. The duration of treatment will be 14 ± 1 days, depending on the clinical judgment of the investigator.

Combination Product: CONTROL GROUP
In this case, the centers where the patients are enrolled will adhere to the Colombian guidelines (Colombian Consensus of the Colombian Association of Infectious Diseases)
Other Name: standard treatment

Eligibility Criteria

Inclusion Criteria: - Patients ≥18 years old. - Laboratory-confirmed SARS-CoV-2 infection: infection confirmed with nasopharyngeal swab by positive RT PCR in the last 48 hours. - Hospital admission for COVID-19 in the previous 48 hours. - Clinical stage 3 (no supplemental oxygen requirement) or 4 (supplemental oxygen requirement for nasal contact lenses or mask) of the WHO classification (see ANNEX 2). - The patient must be able and willing to provide informed written consent before performing study procedures. - Patient confirmed to covid19 as positive by positive PCR test

Exclusion Criteria: - Pregnancy, nursing mothers, and women of childbearing potential who are unable to use adequate contraception. - Known hypersensitivity or other clear contraindication to the use of colchicine. - History of end-stage renal disease (eGFR 5 times the upper limit of normal. - History of pre-existing neuromuscular disease. - Previous severe hematologic disease or bleeding disorders. - Inflammatory bowel disease (Crohn's disease or ulcerative colitis), chronic diarrhea, or malabsorptive syndrome. - Colchicine treatment for other indications. - Treatment with immunosuppressive/immunomodulatory agents, including glucocorticoids, antivirals, antimalarials, and IL 6 antagonists for 30 days prior to enrollment. - Use of other investigational drugs at the time of inclusion, or during the 30 days prior to inclusion. - Any medical condition or disease that, in the opinion of the investigator, may place the patient at unacceptable risk to participate in the study.

Eligibility Gender
Eligibility Age
Minimum: 18 Years

+571 3538100

+571 3538100

Study Chair
Hospital de San Jose

Fundación Universitaria de Ciencias de la Salud
Hospital de San Jose
NCT Number
Antirheumatic Agents
Tubulin Modulators
MeSH Terms
Coronavirus Infections
Severe Acute Respiratory Syndrome